Celgene
Clinical trials sponsored by Celgene, explained in plain language.
-
New drug shows promise for Long-Term control of esophagus inflammation
Disease control CompletedThis study looked at the long-term safety of an experimental drug called CC-93538 for people with eosinophilic esophagitis, a condition where white blood cells build up in the esophagus and cause trouble swallowing. It included 367 adults and teens who had already been in earlier…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:48 UTC
-
New hope for MDS patients: drug may cut blood transfusions
Disease control CompletedThis study tested a drug called luspatercept in 30 Chinese and Japanese adults with a bone marrow disorder (MDS) who needed regular red blood cell transfusions. The goal was to see if the drug could help them go without transfusions for at least 8 weeks. The study was completed a…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:48 UTC
-
New hope for Hard-to-Treat prostate cancer: early trial launched
Disease control CompletedThis early-phase study tested a new drug called CC-94676 in 131 men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to check the drug's safety, find the right dose, and see if it could help control the cance…
Phase: PHASE1 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:46 UTC
-
New pill offers hope for japanese ulcerative colitis patients
Disease control CompletedThis study tested two doses of an oral medication, ozanimod, in 198 Japanese adults with moderate to severe ulcerative colitis. The goal was to see if the drug could reduce symptoms like diarrhea and rectal bleeding compared to a placebo. The trial is now complete, and results wi…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New oral drug shows promise for Long-Term ulcerative colitis control
Disease control CompletedThis study tested the long-term safety and effectiveness of an oral medication called RPC1063 for people with moderate to severe ulcerative colitis. It involved 877 participants who had already been in earlier trials of the same drug. The goal was to see how well the drug control…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in people with blood cancers. It enrolled 5 patients who had already taken the drug in earlier studies and were still benefiting from it. The main goal was to track any side effects that occurred…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
New cell therapy shows promise for Tough-to-Treat multiple myeloma
Disease control CompletedThis study tested a new treatment called bb2121 in people with multiple myeloma, a type of blood cancer. It included patients whose cancer had returned or was hard to treat, as well as those at high risk. The goal was to see how well bb2121 worked and how safe it was. About 312 p…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug shows promise for rare stomach disease
Disease control CompletedThis study tested a drug called CC-93538 in 48 Japanese adults and teenagers with eosinophilic gastroenteritis, a condition where certain white blood cells build up in the stomach and intestines, causing pain and other symptoms. The goal was to see if the drug could reduce these …
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Liver study checks drug safety for patients with organ damage
Knowledge-focused CompletedThis study looked at how the drug golcadomide behaves in people with moderate or severe liver problems compared to healthy volunteers. 29 adults received a single dose to measure drug levels and check for side effects. The goal is to find safe dosing for patients with liver impai…
Phase: PHASE1 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated May 26, 2026 04:38 UTC